[The results of a clinical trial of flurenizid in phthisiopulmonology practice].
Flurenizide, a new home drug preparation, endowed with antituberculosis activity, was administered to 20 patients with freshly detected pulmonary tuberculosis, in combination with etambutole or rifampycin in a daily dose of 0.6 g. After the above chemotherapy, closure of the cavities, diminution in size and consolidation of the foci as well as infiltrates, dispelling of the symptoms of intoxication, and discontinuance of bacteria discharge were observable in 70.0 percent of the cases. The drug is well tolerated by patients and is not associated with side effects. The results obtained permit recommending flurenizide for use in phthisiopulmonological practice.
Il'nyts'kyĭ
I H
IH
Panasiuk
O V
OV
Petrukh
L I
LI
Hud'
M V
MV
Buts'
Ia H
IaH
Mykhal'chuk
V I
VI
Chulovs'ka
U B
UB
Kozubs'kyĭ
Iu O
IuO
Lychkovs'kyĭ
O E
OE
Hel'ner
A S
AS
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002214:Capsules; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D002214:Capsules; D006571:Heterocyclic Compounds; C065925:flurenizid; D004977:Ethambutol; D012293:Rifampin